Zydus receives FDA’s ODD for Desidustat for the treatment of beta-thalassemia
Orphan drug designation (ODD) by the USFDA for Desidustat, provides eligibility for a potential seven-year marketing exclusivity subject to the USFDA approval
Orphan drug designation (ODD) by the USFDA for Desidustat, provides eligibility for a potential seven-year marketing exclusivity subject to the USFDA approval
Exemestane is a key therapeutic used in the treatment of certain types of breast cancer in postmenopausal women
From material selection to cooling tower management, every small decision affects long-term equipment reliability
Upon completion, Kimberly-Clark shareholders are expected to own about 54% of the combined entity, while Kenvue shareholders will hold the remaining 46%
The transaction is expected to be completed within one month from the signing of the definitive agreements.
Basketball legend, entrepreneur, and entertainer Shaquille O’Neal partners with Lilly to encourage Americans to recognize the signs of obstructive sleep apnea and talk to their
Everolimus is an mTOR inhibitor immunosuppressant indicated for the prophylaxis of organ rejection in adult patients in kidney and liver transplantation
The Fast Track Designation was supported by nonclinical data as well as clinical results from the ongoing Phase I/IIa trial evaluating the safety and tolerability
Arora brings over 30 years of experience in the pharmaceutical and healthcare industry
Subscribe To Our Newsletter & Stay Updated